



**CERTIFICATE OF MAILING**

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT  
POSTAGE AS FIRST-CLASS MAIL WITH SUFFICIENT POSTAGE IN AN  
ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231, ON January 28, 2002

*Audrey Boyd*  
January 28, 2002  
DATE

*Do not enter  
03/11/2002  
BAC*

*AF116008*  
*#13*  
*Amdt. Done*  
*2/21/02*

Applicant : Dalemans, et al.  
Appl. No. : 09/581,976  
Filed : June 20, 2000  
Title : VACCINE  
  
Grp./A.U. : 1648  
Examiner : B. Li  
  
Docket No. : B45124

**RECEIVED**  
FEB 20 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Box AF  
Washington, D.C. 20231

**AMENDMENT AND RESPONSE AFTER FINAL**

In response to the Office Action dated August 28, 2001, Applicants respectfully request entry and consideration of this Amendment and Response. A petition for an Extension of Time authorizing the charge of fees for a two-month extension required by this paper to Deposit Account No. 19-2570 is attached. Submitted herewith is a Notice of Appeal with authorization to charge the necessary fees to the above account.. Should the Notice of Appeal or the request for the two-month extension become detached from this Amendment and Response, authorization is granted to charge any necessary fees to Deposit Account No. 19-2570. A declaration by one of the inventors, Dr. Catherine Gérard, is also attached.

**IN THE CLAIMS:**

Please cancel claims Claims 2, 12 and 16-20 without prejudice.

Please amend claims 1, 10 and 13-15 as follows:

A composition comprising an isolated fusion protein selected from the group consisting of E6 or E7 protein and E6/E7 fusion protein from HPV, linked to a protein D or a